Last €22.55 EUR
Change Today -0.18 / -0.79%
Volume 1.4K
TG4 On Other Exchanges
EN Brussels
As of 11:24 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/8/13 - €39.80
52 Week Low
12/4/13 - €16.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, is engaged in developing and commercializing ophthalmic and oncology medicines in Belgium and interntionally. The company offers JETREA for the treatment of symptomatic vitreomacular traction. It has a collaboration agreement with BioInvent International AB to develop anti-factor VIII, an anti-coagulation treatment for various indications, such as the prevention and treatment of deep vein thrombosis, and the treatment of atrial fibrillation; and anti-placental growth factor, an anti-angiogenic component for the treatment of various disorders, including cancer, age-related macula degeneration, retinopathy, and inflammation. The company also has a research and license agreement with Bharat Biotech; a production agreement with Fujifilm Diosynth Biotechnologies UK Limited; a license agreement Grifols and NuVue Technologies, Inc.; a life sciences research partnership with VZW; agreements with Eleven Biotherapeutics, Bicycle Therapeutics, and Flanders Institute for Biotechnology; and cooperation agreements with Centrum voor Moleculaire en Vasculaire Biologie and KULeuven. ThromboGenics NV was founded in 1991 and is headquartered in Leuven, Belgium.

154 Employees
Last Reported Date: 04/9/14
Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €448.0K
Compensation as of Fiscal Year 2013.

thrombogenics nv (TG4) Key Developments

ThromboGenics NV Reports Earnings Results for the Year Ended December 31, 2013

ThromboGenics NV reported earnings results for the year ended December 31, 2013. For the year, the company reported EPS of EUR 0.71 per diluted share compared to EUR 0.84 per diluted share, for the year ended December 31, 2012. Sales were EUR 21.72 million, compared to EUR 22 million for the year ended December 31, 2012. Operating income was EUR 25.51 million, compared to EUR 29.1 million for the year ended December 31, 2012.

ThromboGenics NV(ENXTBR:THR) dropped from Brussels BEL 20 Index

ThromboGenics NV will be removed from the Brussels BEL 20 Index.

ThromboGenics NV Presents at KBC Healthcare Conference, Mar-20-2014

ThromboGenics NV Presents at KBC Healthcare Conference, Mar-20-2014 . Venue: KBC Building, Grand Place, Grote Markt 17, 1000 Brussels, Belgium. Speakers: Chris Buyse, Chief Financial Officer and Executive Director, Patrik De Haes, Chief Executive Officer and Executive Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €22.55 EUR -0.18

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies

Industry Analysis


Industry Average

Valuation TG4 Industry Range
Price/Earnings 31.5x
Price/Sales 7.2x
Price/Book 3.1x
Price/Cash Flow 30.7x
TEV/Sales 5.7x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at